<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77313">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099058</url>
  </required_header>
  <id_info>
    <org_study_id>M14-237</org_study_id>
    <secondary_id>2014-003154-14</secondary_id>
    <nct_id>NCT02099058</nct_id>
  </id_info>
  <brief_title>A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors</brief_title>
  <official_title>A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and
      preliminary efficacy of ABBV-399 in subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Collect all adverse events at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half life</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the proportion of the subjects who have a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PFS is defined as the time from the first dose date of ABBV-399 to either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR is defined as the time from the subject's initial CR or PR to the time of disease progression.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A (ABBV-399)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABBV-399.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (ABBV 399 plus Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 to be evaluated with Erlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (ABBV-399 plus Cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 to be evaluated with Cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D (ABBV-399 plus Bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 to be evaluated with Bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F (ABBV-399)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABBV-399.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E (ABBV-399 plus Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-399 to be evaluated with Nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-399</intervention_name>
    <description>It is administered by infusion in 21-day dosing cycles.</description>
    <arm_group_label>Cohort A (ABBV-399)</arm_group_label>
    <arm_group_label>Cohort B (ABBV 399 plus Erlotinib)</arm_group_label>
    <arm_group_label>Cohort C (ABBV-399 plus Cetuximab)</arm_group_label>
    <arm_group_label>Cohort D (ABBV-399 plus Bevacizumab)</arm_group_label>
    <arm_group_label>Cohort F (ABBV-399)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>It is administered orally everyday.</description>
    <arm_group_label>Cohort B (ABBV 399 plus Erlotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>It is an intravenous infusion administered every 7 days.</description>
    <arm_group_label>Cohort C (ABBV-399 plus Cetuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>It is an intravenous infusion administered every 21 days.</description>
    <arm_group_label>Cohort D (ABBV-399 plus Bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>It is an intravenous infusion administered every 14 days.</description>
    <arm_group_label>Cohort E (ABBV-399 plus Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-399</intervention_name>
    <description>It is administered by infusion in 28-day dosing cycles.</description>
    <arm_group_label>Cohort B (ABBV 399 plus Erlotinib)</arm_group_label>
    <arm_group_label>Cohort C (ABBV-399 plus Cetuximab)</arm_group_label>
    <arm_group_label>Cohort D (ABBV-399 plus Bevacizumab)</arm_group_label>
    <arm_group_label>Cohort F (ABBV-399)</arm_group_label>
    <arm_group_label>Cohort E (ABBV-399 plus Nivolumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have advanced solid tumor that is not amenable to surgical resection or
             other approved therapeutic options that have demonstrated clinical benefit but based
             on evidence gathered in this study or from external sources, the Sponsor in
             consultation with the Investigators, may decide to limit to specific tumor types.

          2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
             2.

          3. Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors
             (RECIST) version 1.1.

          4. Subject has one archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor
             tissue confirmed available for analyses.

          5. Subject has adequate bone marrow, renal, and hepatic function.

          6. Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to initiation of treatment.

          7. Subjects in the combination therapy arms must be eligible to receive erlotinib,
             cetuximab, bevacizumab or nivolumab per most current prescribing information, or at
             the discretion of the Investigator.

        Exclusion Criteria:

          1. Subject has received anticancer therapy including chemotherapy, radiation therapy,
             immunotherapy, biologic, or any investigational therapy within a period of 21 days or
             herbal therapy within 7 days prior to the first dose of ABBV-399.

          2. Subject has known uncontrolled metastases to the central nervous system (CNS).
             Subjects with brain metastases are eligible provided they have shown clinical and
             radiographic stable disease for at least 4 weeks after definitive therapy and have
             not used steroids for at least 4 weeks prior to first dose of ABBV-399.

          3. Subject has unresolved adverse events &gt;= Grade 2 from prior anticancer therapy,
             except for alopecia or anemia.

          4. Subject has had major surgery within 21 days prior to the first dose of ABBV-399.

          5. Subject has a clinically significant uncontrolled condition(s).

          6. Subject has history of major immunologic reaction to any Immunoglobulin G (IgG)
             containing agent.

          7. Subjects enrolled on the combination therapy phase must satisfy the above exclusion
             criteria and also the following:

               -  Subjects may not receive ABBV-399 in combination with erlotinib, cetuximab,
                  bevacizumab or nivolumab if they have any medical condition which in the opinion
                  of the Investigator places the subject at an unacceptably high risk for
                  toxicities from the combination.

                  i. Subjects may not receive cetuximab if they have K-ras mutation. ii. Subjects
                  may not receive bevacizumab if they have squamous Non-small-cell lung carcinoma
                  (NSCLC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louie Naumovski, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123761</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123761, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148295</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148295, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129805</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129805, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123759</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123759, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136995</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136995, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129804</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129804, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135314</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135314, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149857</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149857, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149858</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149858, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 143798</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 143798, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123763</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123763, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129802</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129802, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123760</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 123760, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154528</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154528, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154648</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154648, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149742</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149742, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151570</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151570, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132747</name>
      <address>
        <city>Villejuif, Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132747, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
